Citations

Clear

4847 citation(s) found for "Yu, Eric".

Familial Hypercholesterolemia in the Electronic Medical Records and Genomics Network: Prevalence, Penetrance, Cardiovascular Risk, and Outcomes After Return of Results
Dikilitas, Ozan , Sherafati, Alborz , Saadatagah, Seyedmohammad , Kochan, David C., Anderson, Katherine , Chung, Wendy K. , Hebbring, Scott J. , Salvati, Zachary , Sharp, Richard R. , Sturm, Amy C. , Gibbs, Richard A. , Rowley, Robb , Linder, Jodell E. , Perez, Emma , Peterson, Josh F. , Jarvik, Gail P. , Roden, Dan M. , Manolio, Teri A. , Satterfield, Benjamin A , Anderson, Katherine C , Chung, Wendy K. , Salvati, Zachary M , Sharp, Richard R , Sturm, Amy C , Rowley, Robb , Venner, Eric , Linder, Jodell E , Jones, Laney K , Peterson, Josh F , Jarvik, Gail P , Rehm, Heidi L , Zouk, Hana , Roden, Dan M. , Williams, Marc S , Manolio, Teri A , Kullo, Iftikhar J , Dikilitas, Ozan , Satterfield, Benjamin A. , Venner, Eric , Rehm, Heidi L. , Kullo, Iftikhar J.

Mayo Clinic

Circulation: Genomic and Precision Medicine | February 22, 2023 | Volume: 16 | Issue: 2 | Pages: No page available

10.1161/circgen.122.003816 | PMID 37071725 Get It

Background: The implications of secondary findings detected in large-scale sequencing projects remain uncertain. We assessed prevalence and penetrance of pathogenic familial hypercholesterolemia (FH) variants, their association with coronary heart disease (CHD), and 1-year outcomes following return of results in phase III of the electronic medical records and genomics network. Methods: Adult participants (n=18 544) at 7 sites were enrolled in a prospective cohort study to assess the clinical impact of returning results from targeted sequencing of 68 actionable genes, including LDLR , APOB , and PCSK9 . FH variant prevalence and penetrance (defined as low-density lipoprotein cholesterol >155 mg/dL) were estimated after excluding participants enrolled on the basis of hypercholesterolemia. Multivariable logistic regression was used to estimate the odds of CHD compared to age- and sex-matched controls without FH-associated variants. Process (eg, referral to a specialist or ordering new tests), intermediate (eg, new diagnosis of FH), and clinical (eg, treatment modification) outcomes within 1 year after return of results were ascertained by electronic health record review. Results: The prevalence of FH-associated pathogenic variants was 1 in 188 (69 of 13,019 unselected participants). Penetrance was 87.5%. The presence of an FH variant was associated with CHD (odds ratio, 3.02 [2.00–4.53]) and premature CHD (odds ratio, 3.68 [2.34–5.78]). At least 1 outcome occurred in 92% of participants; 44% received a new diagnosis of FH and 26% had treatment modified following return of results. Conclusions: In a multisite cohort of electronic health record–linked biobanks, monogenic FH was prevalent, penetrant, and associated with presence of CHD. Nearly half of participants with an FH-associated variant received a new diagnosis of FH and a quarter had treatment modified after return of results. These results highlight the potential utility of sequencing electronic health record–linked biobanks to detect FH.
Developing an Echocardiography-Based, Automatic Deep Learning Framework for the Differentiation of Increased Left Ventricular Wall Thickness Etiologies
Chao, Chieh‐Ju , Jeong, Jiwoong , Farina, Juan M. , Seri, Amith Reddy , Barry, Timothy , Newman, Hana , Campany, Megan , Abdou, Merna , O’Shea, Michael , Smith, Sean D. , Abraham, Bishoy, Hosseini, Seyedeh Maryam , Wang, Yuxiang , Lester, Steven J., Alsidawi, Said , Wilansky, Susan , Steidley, Eric, Rosenthal, Julie , Appleton, Christopher P., Shen, Win‐Kuang , Grogan, Martha , Kane, Garvan C. , Oh, Jae K. , Patel, Bhavik N. , Arsanjani, Reza , Banerjee, Imon , O’Shea, Michael , Chao, Chieh-Ju , Jeong, Jiwoong Jason, Farina, Juan M , Seri, Amith R, Barry, Timothy , O'Shea, Michael, Smith, Sean , Hosseini, Seyedeh Maryam , Lester, Steven, Alsidawi, Said , Arsanjani, Reza , Banerjee, Imon , Li, James , O’Shea, Michael, Abraham, Bishoy

Mayo Clinic

Journal of Imaging | February 20, 2023 | Volume: 9 | Issue: 2 | Pages: 48

10.3390/jimaging9020048 | PMID 36826967 Get It

Aims:Increased left ventricular (LV) wall thickness is frequently encountered in transthoracic echocardiography (TTE). While accurate and early diagnosis is clinically important, given the differences in available therapeutic options and prognosis, an extensive workup is often required to establish the diagnosis. We propose the first echo-based, automated deep learning model with a fusion architecture to facilitate the evaluation and diagnosis of increased left ventricular (LV) wall thickness. Methods and Results: Patients with an established diagnosis of increased LV wall thickness (hypertrophic cardiomyopathy (HCM), cardiac amyloidosis (CA), and hypertensive heart disease (HTN)/others) between 1/2015 and 11/2019 at Mayo Clinic Arizona were identified. The cohort was divided into 80%/10%/10% for training, validation, and testing sets, respectively. Six baseline TTE views were used to optimize a pre-trained InceptionResnetV2 model. Each model output was used to train a meta-learner under a fusion architecture. Model performance was assessed by multiclass area under the receiver operating characteristic curve (AUROC). A total of 586 patients were used for the final analysis (194 HCM, 201 CA, and 191 HTN/others). The mean age was 55.0 years, and 57.8% were male. Among the individual view-dependent models, the apical 4-chamber model had the best performance (AUROC: HCM: 0.94, CA: 0.73, and HTN/other: 0.87). The final fusion model outperformed all the view-dependent models (AUROC: HCM: 0.93, CA: 0.90, and HTN/other: 0.92). Conclusion: The echo-based InceptionResnetV2 fusion model can accurately classify the main etiologies of increased LV wall thickness and can facilitate the process of diagnosis and workup.
Orbital resection by intranasal technique (ORBIT): A new classification system for reporting endoscopically resectable primary benign orbital tumors
Jafari, Aria , Adappa, Nithin D. , Anagnos, Vincent J., Chalian, Ara A., Chambers, Christopher B. , Dallan, Iacopo , Freitag, Suzanne K. , Miranda, Juan Carlos Fernández, Gardner, Paul A. , Harvey, Richard J. , Huang, Qian , Humphreys, Ian M. , Kennedy, David W. , Lee, John Y. K. , Lehmann, Ashton E. , McKinney, Kibwei A. , Moreau, Annie, Nyquist, Gurston , Adappa, Nithin D. , Pribitkin, Edmund A. , Rabinowitz, Mindy, Sacks, Raymond , Sharma, Dhruv , Stefko, S. Tonya, Stokken, Janalee K., Workman, Alan D. , Wu, Arthur W. , Yu, Jen Y., Zhang, Matthew , Zhou, Bing , Stokken, Janalee K. , Humphreys, Ian M , Lehmann, Ashton E , Snyderman, Carl H , Wang, Eric W , Wu, Arthur W , Bleier, Benjamin , Carlson, Matthew L , Harvey, Richard J , Adappa, Nithin D. , Anagnos, Vincent , Campbell, Raewyn Gay , Castelnuovo, Paolo , Chitguppi, Chandala , Rassi, Edward El , Ferreira, Manuel Marques , Gudis, David A. , Locatelli, Davide , Prepageran, Narayanan , Rosen, Marc R , Bleier, Benjamin S.

Mayo Clinic

International Forum of Allergy & Rhinology | February 17, 2023 | Volume: 13 | Issue: 10 | Pages: 1852-1863

10.1002/alr.23141 | PMID 36808854 Get It

AbstractBackgroundThe Cavernous Hemangioma Exclusively Endonasal Resection (CHEER) staging system has become the gold standard for outcomes reporting in endoscopic orbital surgery for orbital cavernous hemangiomas (OCHs). A recent systematic review demonstrated similar outcomes between OCHs and other primary benign orbital tumors (PBOTs). Therefore, we hypothesized that a simplified and more comprehensive classification system could be developed to predict surgical outcomes of other PBOTs.MethodsPatient and tumor characteristics as well as surgical outcomes from 11 international centers were recorded. All tumors were retrospectively assigned an Orbital Resection by Intranasal Technique (ORBIT) class and stratified based on surgical approach as either exclusively endoscopic or combined (endoscopic and open). Outcomes based on approach were compared using chi‐squared or Fisher's exact tests. The Cochrane‐Armitage test for trend was used to analyze outcomes by class.ResultsFindings from 110 PBOTs from 110 patients (age 49.0 ± 15.0 years, 51.9% female) were included in the analysis. Higher ORBIT class was associated with a lower likelihood of gross total resection (GTR). GTR was more likely to be achieved when an exclusively endoscopic approach was utilized (p < 0.05). Tumors resected using a combined approach tended to be larger, to present with diplopia, and to have an immediate postoperative cranial nerve palsy (p < 0.05).ConclusionEndoscopic treatment of PBOTs is an effective approach, with favorable short‐term and long‐term postoperative outcomes as well as low rate of adverse events. The ORBIT classification system is an anatomic‐based framework that effectively facilitates high‐quality outcomes reporting for all PBOTs.
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival
Morra, Anna , Andrulis, Irene L. , Beckmann, Matthias W. , Bolla, Manjeet K. , Camp, Nicola J. , Cessna, Melissa H., Chang‐Claude, Jenny , Collaborators, NBCS, Daly, Mary B., Easton, Douglas F. , Eccles, Diana M., Evans, D. Gareth , Fasching, Peter A. , Flyger, Henrik, García‐Closas, Montserrat , Gündert, Melanie , Hahnen, Eric , Haiman, Christopher A. , Hamann, Ute, Harrington, Patricia, Hoppe, Reiner , Howell, Anthony , Investigators, ABCTB, Investigators, kConFab, Janni, Wolfgang, Johnson, Nichola , Kristensen, Vessela N. , Lindblom, Annika , Mannermaa, Arto , Mavroudis, Dimitrios, Nevelsteen, Ines, Neven, Patrick , Obi, Nadia , Offit, Kenneth , Park‐Simon, Tjoung‐Won , Patel, Alpa V. , Phillips, Kelly‐Anne , Plaseska-Karanfilska, Dijana, Rack, Brigitte , Rhenius, Valerie , Sawyer, Elinor J. , Schmutzler, Rita K. , Schuetze, Sabine, Shah, Mitul , Smichkoska, Snezhana , Tollenaar, Rob A.�E.�M. , Tomlinson, Ian , Vachon, Celine M. , Veen, Elke M. van , Wang, Qin , Wendt, Camilla, Wildiers, Hans , Adank, Muriel A. , Hooning, Maartje J. , Eccles, Diana , Plaseska‐Karanfilska, Dijana , Eccles, Diana , Evans, D Gareth , García-Closas, Montserrat , Phillips, Kelly-Anne , Wildiers, Hans , Lindblom, Annika , Plaseska-Karanfilska, Dijana , Sawyer, Elinor J , Schreurs, Maartje A. C. , Anton‐Culver, Hoda , Augustinsson, Annelie , Behrens, Sabine , Bojesen, Stig E. , Brauch, Hiltrud , Broeks, Annegien , Buys, Saundra S. , Castelao, Jose E. , Chung, Wendy K. , Colonna, Sarah V. , Couch, Fergus J. , Cox, Angela , Cross, Simon S. , Czene, Kamila , Dennis, Joe , Devilee, Peter , Dörk, Thilo , Dunning, Alison M. , Dwek, Miriam , Eriksson, Mikael , Fehm, Tanja , Figueroa, Jonine D. , Gabrielson, Marike , Gago-Domínguez, Manuela , García-Sáenz, José Á. , Genkinger, Jeanine M. , Graßmann, Felix , Hartikainen, Jaana M. , Hopper, John L. , Houlston, Richard S. , Jakubowska, Anna , Jernström, Helena , John, Esther M. , Jones, Michael E. , Kurian, Allison W. , Lambrechts, Diether , Marchand, Loı̈c Le , Lubiński, Jan , Lux, Michael P. , Mulligan, Anna Marie , Muranen, Taru , Nevanlinna, Heli , Newman, William G. , Olshan, Andrew F. , Peterlongo, Paolo , Polley, Eric C. , Presneau, Nadège , Pylkäs, Katri , Radice, Paolo , Rashid, Muhammad Usman , Robson, Mark E. , Romero, Atocha , Saloustros, Emmanouil , Scott, Christopher, Southey, Melissa C. , Tapper, William , Teras, Lauren R. , Tomczyk, Katarzyna , Troester, Melissa A. , Vachon, Celine M. , Winqvist, Robert , Ziogas, Argyrios , Hall, Per N , Pharoah, Paul D.P. , Hollestelle, Antoinette , Schmidt, Marjanka K.

Mayo Clinic

No container title available | February 13, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2569372/v1 | PMID 36824750 Get It

Abstract Breast cancer (BC) patients with a germline CHEK2 c.1100delC variant have an increased risk of contralateral BC (CBC) and worse BC-specific survival (BCSS) compared to non-carriers. We aimed to assess the associations of CHEK2 c.1100delC, radiotherapy, and systemic treatment with CBC risk and BCSS. Analyses were based on 82,701 women diagnosed with invasive BC including 963 CHEK2 c.1100delC carriers; median follow-up was 9.1 years. Differential associations of treatment by CHEK2 c.1100delC status were tested by including interaction terms in a multivariable Cox regression model. A multi-state model was used for further insight into the relation between CHEK2 c.1100delC status, treatment, CBC risk and death. There was no evidence for differential associations of therapy with CBC risk by CHEK2 c.1100delC status The strongest association with reduced CBC risk was observed for the combination of chemotherapy and endocrine therapy [HR(95%CI): 0.66 (0.55–0.78)]. No association was observed with radiotherapy. Results from the multi-state model showed shorter BCSS for CHEK2 c.1100delC carriers versus non-carriers also after accounting for CBC occurrence [HR(95%CI) :1.30 (1.09–1.56)]. In conclusion, systemic therapy was associated with reduced CBC risk irrespective of CHEK2 c.1100delC status. Moreover, CHEK2 c.1100delC carriers had shorter BCSS, which appears not to be fully explained by their CBC risk. (Main MS: 3201 words)
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection
Sims, Matthew , Khanna, Sahil , Louie, Thomas , Kelly, Colleen , Hohmann, Elizabeth , Wang, Elaine E. L., Oneto, Caterina , Cohen, Stuart H. , Berenson, Charles S., Korman, Louis Y. , Lee, Christine , Lashner, Bret A., Kraft, Colleen S., Ramesh, Mayur , Silverman, Michael H. , Pardi, Darrell S. , Hasson, Brooke , McGovern, Barbara , Moltke, Lisa Von, Investigators, ECOSPOR IV, Hemaidan, Anmar, Kumar, Princy , Misra, Bharat , Nathan, Richard, Pullman, John, Williams, Jeffrey G., Acosta, Idalia, Odio, Alberto, Smith, Kent, Hansen, Val, Georgetson, Michael, Sheikh, Aasim , Arimie, Calin, Andrade, Gladys, O’Marro, Steven, Esfandyari, Tuba, Ritter, Timothy E., Baird, Ian Mcnicol, Colman, Ronald, Hernandez, Lilliam, Adams, Atoya, Walton, Marie, Arsenescu, Razvan, Shapiro, Max, Cook, Paul, Heuer, Marvin, Bogdanovich, Tatiana, Grimard, Doria, Butt, Debra, Gauthier, Stephanie , Guímont, Chantal, Kreines, Michael, Berman, Larry, Bennett, Michael , Fogel, Ronald, Gutierrez, Juan Carlos Moises, Pedersen, P.C. , Bressler, Adam, Nadar, Venkatesh, Newton, Eric, Abbas, Jalal, Jamal, Aamir, Benjamin, Sabrina, Ayub, Kamran, Oguchi, Godson, Pinero, Jose, Ramesh, Gowrappala, Sepe, Paul S., Brook, Loren, Ruthardt, Frederick, Surace, Lindsey, Hussain, Ayub, Rutland, Travis J., Schmalz, Micahel, Degala, Gourisankar, Phillips, Raymond E. , Stock, Kent, Bullock, Jeffrey, Onwueme, Kenolisa, Feuerstadt, Paul , Huang, Edward S. , Lee, Christine H. , Kraft, Colleen S. , Silverman, Michael, De, Ananya, Memisoglu, Asli, Lombardi, David A., Investigators, ECOSPOR IV, Nguyen, Hien , Tran, Huy, Smith, Kent, Weinstock, Leonard B. , Garcia‐Diaz, Julia , Colman, Ronald, Patel, Meenakshi, Shapiro, Max, Cook, Paul, Steiner, Theodore S. , Butt, Debra, Daley, Peter , Gauthier, Stephanie, Berman, Larry, Bennett, Michael, Pedersen, Peder, Newton, Eric, Diaz, Jorge, Abbas, Jalal, DuPont, Herbert L. , Jamal, Aamir, Talreja, Neetu, Ayub, Kamran, Phillips, Raymond

Mayo Clinic

JAMA Network Open | February 13, 2023 | Volume: 6 | Issue: 2 | Pages: e2255758

10.1001/jamanetworkopen.2022.55758 | PMID 36780159 Get It

ImportanceA safe and effective treatment for recurrent Clostridioides difficile infection (CDI) is urgently needed. Antibiotics kill toxin-producing bacteria but do not repair the disrupted microbiome, which promotes spore germination and infection recurrence.ObjectivesTo evaluate the safety and rate of CDI recurrence after administration of investigational microbiome therapeutic SER-109 through 24 weeks.Design, Setting, and ParticipantsThis phase 3, single-arm, open-label trial (ECOSPOR IV) was conducted at 72 US and Canadian outpatient sites from October 2017 to April 2022. Adults aged 18 years or older with recurrent CDI were enrolled in 2 cohorts: (1) rollover patients from the ECOSPOR III trial who had CDI recurrence diagnosed by toxin enzyme immunoassay (EIA) and (2) patients with at least 1 CDI recurrence (diagnosed by polymerase chain reaction [PCR] or toxin EIA), inclusive of their acute infection at study entry.InterventionsSER-109 given orally as 4 capsules daily for 3 days following symptom resolution after antibiotic treatment for CDI.Main Outcomes and MeasuresThe main outcomes were safety, measured as the rate of treatment-emergent adverse events (TEAEs) in all patients receiving any amount of SER-109, and cumulative rates of recurrent CDI (toxin-positive diarrhea requiring treatment) through week 24 in the intent-to-treat population.ResultsOf 351 patients screened, 263 were enrolled (180 [68.4%] female; mean [SD] age, 64.0 [15.7] years); 29 were in cohort 1 and 234 in cohort 2. Seventy-seven patients (29.3%) were enrolled with their first CDI recurrence. Overall, 141 patients (53.6%) had TEAEs, which were mostly mild to moderate and gastrointestinal. There were 8 deaths (3.0%) and 33 patients (12.5%) with serious TEAEs; none were considered treatment related by the investigators. Overall, 23 patients (8.7%; 95% CI, 5.6%-12.8%) had recurrent CDI at week 8 (4 of 29 [13.8%; 95% CI, 3.9%-31.7%] in cohort 1 and 19 of 234 [8.1%; 95% CI, 5.0%-12.4%] in cohort 2), and recurrent CDI rates remained low through 24 weeks (36 patients [13.7%; 95% CI, 9.8%-18.4%]). At week 8, recurrent CDI rates in patients with a first recurrence were similarly low (5 of 77 [6.5%; 95% CI, 2.1%-14.5%]) as in patients with 2 or more recurrences (18 of 186 [9.7%; 95% CI, 5.8%-14.9%]). Analyses by select baseline characteristics showed consistently low recurrent CDI rates in patients younger than 65 years vs 65 years or older (5 of 126 [4.0%; 95% CI, 1.3%-9.0%] vs 18 of 137 [13.1%; 95% CI, 8.0%-20.0%]) and patients enrolled based on positive PCR results (3 of 69 [4.3%; 95% CI, 0.9%-12.2%]) vs those with positive toxin EIA results (20 of 192 [10.4%; 95% CI, 6.5%-15.6%]).Conclusions and RelevanceIn this trial, oral SER-109 was well tolerated in a patient population with recurrent CDI and prevalent comorbidities. The rate of recurrent CDI was low regardless of the number of prior recurrences, demographics, or diagnostic approach, supporting the beneficial impact of SER-109 for patients with CDI.Trial RegistrationClinicalTrials.gov identifier: NCT03183141
Bayesian penalized likelihood PET reconstruction impact on quantitative metrics in diffuse large B-cell lymphoma
Young, Jason R. , Mugu, Vamshi , Johnson, Geoffrey B. , Ehman, Eric C. , Packard, Annie T. , Homb, Andrew, Nathan, Mark A., Thanarajasingam, Gita , Kemp, Bradley J. , Mugu, Vamshi K, Homb, Andrew C, Johnson, Geoffrey B , Young, Jason R

Mayo Clinic

Medicine | February 10, 2023 | Volume: 102 | Issue: 6 | Pages: e32665

10.1097/md.0000000000032665 | PMID 36820562 Get It

Evaluate the quantitative, subjective (Deauville score [DS]) and reader agreement differences between standard ordered subset expectation maximization (OSEM) and Bayesian penalized likelihood (BPL) positron emission tomography (PET) reconstruction methods. A retrospective review of 104 F-18 fluorodeoxyglucose PET/computed tomography (CT) exams among 52 patients with diffuse large B-cell lymphoma. An unblinded radiologist moderator reviewed both BPL and OSEM PET/CT exams. Four blinded radiologists then reviewed the annotated cases to provide a visual DS for each annotated lesion. Significant (P < .001) differences in BPL and OSEM PET methods were identified with greater standard uptake value (SUV) maximum and SUV mean for BPL. The DS was altered in 25% of cases when BPL and OSEM were reviewed by the same radiologist. Interobserver DS agreement was higher for OSEM (>1 cm lesion = 0.89 and ≤1 cm lesion = 0.84) compared to BPL (>1 cm lesion = 0.85 and ≤1 cm lesion = 0.81). Among the 4 readers, average intraobserver visual DS agreement between OSEM and BPL was 0.67 for lesions >1cm and 0.4 for lesions ≤1 cm. F-18 Fluorodeoxyglucose PET/CT of diffuse large B-cell lymphoma reconstructed with BPL has higher SUV values, altered DSs and reader agreement when compared to OSEM. This report finds volumetric PET measurements such as metabolic tumor volume to be similar between BPL and OSEM PET reconstructions. Efforts such as adoption of European Association Research Ltd accreditation should be made to harmonize PET data with an aim at balancing the need for harmonization and sensitivity for lesion detection.
Imaging of Small-Bowel Neuroendocrine Neoplasms: AJR Expert Panel Narrative Review
Navin, Patrick J. , Ehman, Eric C. , Liu, Jason B. , Gupta, Akshya , Laghi, Andrea , Yoo, Don C. , Schima, Wolfgang , Sheedy, Shannon P. , Navin, Patrick , Hálfdánarson, Þorvarður R. , Carucci, Laura R.

Mayo Clinic

American Journal of Roentgenology | February 8, 2023 | Volume: 221 | Issue: 3 | Pages: 289-301

10.2214/ajr.22.28877 | PMID 36752369 Get It

Expectations and clinical meaningfulness of randomized controlled trials
Petersen, Ronald C. , Aisen, Paul , Andrews, J. Scott , Matthews, Brandy R., Siemers, Eric , Weber, Christopher J., Carrillo, María C. , Atri, Alireza , Rentz, Dorene M.

Mayo Clinic

Alzheimer's & Dementia | February 7, 2023 | Volume: 19 | Issue: 6 | Pages: 2730-2736

10.1002/alz.12959 | PMID 36748826 Get It

Abstract Alzheimer's disease (AD) clinical trials are designed and powered to detect the impact of a therapeutic intervention, and there has been considerable discussion on what constitutes a clinically meaningful change in those receiving treatment versus placebo. The pathology of AD is complex, beginning many years before clinical symptoms are detectable, with multiple potential opportunities for therapeutic engagement. Introducing treatment strategies early in the disease and assessing meaningful change over the course of an 18‐month clinical trial are critical to understanding the value to an effective intervention. With new clinical trial data expected soon on emerging therapeutics from several AD studies, the Alzheimer's Association convened a work group of experts to discuss key considerations for interpreting data from cognitive and functional measures and what is considered a clinically meaningful benefit or meaningful slowing of this fatal disease. Our expectations of outcomes from therapeutic interventions in AD may need to be modified.
Meniscal and Articular Cartilage Predictors of Outcome After Revision ACL Reconstruction: A 6-Year Follow-up Cohort Study
Group, The MARS, Wright, Rick W. , Haas, Amanda K. , Pennings, Jacquelyn S. , Cooper, Daniel E. , Dunn, Warren R. , Lantz, Brett A., Albright, John P., Amendola, Annunziato , Andrish, Jack T. , Annunziata, Christopher C., Arciero, Robert A. , Bach, Bernard R. , Baker, Champ L., Bartolozzi, Arthur R. , Baumgarten, Keith M. , Bechler, Jeffery R., Berg, Jeffrey H., Bernas, Geoffrey A., Brockmeier, Stephen F. , Bush‐Joseph, Charles A., Butler, J. Brad, Carey, James L. , Carpenter, James E. , Cole, Brian J. , Cooper, Jonathan M. , Cox, Charles L. , Creighton, R. Alexander , Dahm, Diane L., Flanigan, David C. , Frederick, Robert W., Ganley, Theodore J. , Garofoli, Elizabeth A. , Gatt, Charles J. , Gecha, Steven R., Hame, Sharon L. , Hannafin, Jo A., Harner, Christopher D. , Harris, Norman Lindsay, Hechtman, Keith S., Hershman, Elliott B., Hoellrich, Rudolf G., Johnson, David C. , Kaeding, Christopher C. , Kamath, Ganesh V. , Klootwyk, Thomas E., Levy, Bruce A. , Benjamin, C. , Maiers, G. Peter, Marx, Robert G. , Matava, Matthew J. , Mathien, Gregory M., McCarty, Eric C. , McCormack, Robert G. , Miller, Bruce S. , Nissen, Carl W. , O’Neill, Daniel F., Parker, Richard D., Purnell, Mark L., Ramappa, Arun J. , Rauh, Michael A. , Rettig, Arthur C., Sekiya, Jon K., Slauterbeck, James R., Smith, Matthew V. , Spang, Jeffrey T. , Svoboda, LTC Steven J., Taft, Timothy N., Tenuta, Joachim J., Tingstad, Edwin M., Vidal, Armando F. , Viskontas, Darius G., White, Richard A., Williams, James S., Wolcott, Michelle L., York, James J. , Svoboda, Steven J. , McCarty, Eric C , Group, The MARS, Huston, Laura J. , Allen, Christina R. , DeBerardino, Thomas M. , Spindler, Kurt P , Stuart, Michael J. , Brophy, Robert H. , Campbell, John , David, Tal S. , Giffin, J. Robert , Johnson, David C., Johnson, Timothy S. , Jones, Morgan H. , Marx, Robert G. , McAllister, David R. , Owens, Brett D. , Shea, Kevin G. , Sherman, Orrin H. , Vidal, Armando F. , Wolf, Brian R.

Mayo Clinic

The American Journal of Sports Medicine | February 3, 2023 | Volume: 51 | Issue: 3 | Pages: 605-614

10.1177/03635465231151389 | PMID 36734487 Get It

Background: Meniscal and chondral damage is common in the patient undergoing revision anterior cruciate ligament (ACL) reconstruction. Purpose: To determine if meniscal and/or articular cartilage pathology at the time of revision ACL surgery significantly influences a patient’s outcome at 6-year follow-up. Study Design: Cohort study; Level of evidence, 3. Methods: Patients undergoing revision ACL reconstruction were prospectively enrolled between 2006 and 2011. Data collection included baseline demographics, surgical technique, pathology, treatment, and scores from 4 validated patient-reported outcome instruments: International Knee Documentation Committee (IKDC), Knee injury and Osteoarthritis Outcome Score (KOOS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Marx Activity Rating Scale. Patients were followed up at 6 years and asked to complete the identical set of outcome instruments. Regression analysis assessed the meniscal and articular cartilage pathology risk factors for clinical outcomes 6 years after revision ACL reconstruction. Results: An overall 1234 patients were enrolled (716 males, 58%; median age, 26 years). Surgeons reported the pathology at the time of revision surgery in the medial meniscus (45%), lateral meniscus (36%), medial femoral condyle (43%), lateral femoral condyle (29%), medial tibial plateau (11%), lateral tibial plateau (17%), patella (30%), and trochlea (21%). Six-year follow-up was obtained on 79% of the sample (980/1234). Meniscal pathology and articular cartilage pathology (medial femoral condyle, lateral femoral condyle, lateral tibial plateau, trochlea, and patella) were significant drivers of poorer patient-reported outcomes at 6 years (IKDC, KOOS, WOMAC, and Marx). The most consistent factors driving outcomes were having a medial meniscal excision (either before or at the time of revision surgery) and patellofemoral articular cartilage pathology. Six-year Marx activity levels were negatively affected by having either a repair/excision of the medial meniscus (odds ratio range, 1.45-1.72; P≤ .04) or grade 3-4 patellar chondrosis (odds ratio, 1.72; P = .04). Meniscal pathology occurring before the index revision surgery negatively affected scores on all KOOS subscales except for sports/recreation ( P < .05). Articular cartilage pathology significantly impaired all KOOS subscale scores ( P < .05). Lower baseline outcome scores, higher body mass index, being a smoker, and incurring subsequent surgery all significantly increased the odds of reporting poorer clinical outcomes at 6 years. Conclusion: Meniscal and chondral pathology at the time of revision ACL reconstruction has continued significant detrimental effects on patient-reported outcomes at 6 years after revision surgery.
Preoperative electrodiagnostic studies and postoperative outcomes for ulnar mononeuropathy at the elbow: A systematic review
Meiling, James B. , Schappell, Justin B., Twohey, Eric E. , Cushman, Daniel M. , Meiling, James B , Twohey, Eric , Prokop, Larry J.

Mayo Clinic

PM&R | February 2, 2023 | Volume: 15 | Issue: 10 | Pages: 1326-1334

10.1002/pmrj.12952 | PMID 36730149 Get It

AbstractObjectiveTo analyze the association between preoperative electrodiagnostic (EDX) studies and postoperative pain and functional outcomes following ulnar nerve decompression and/or transposition for ulnar neuropathy at the elbow (UNE).Literature SurveyProtocol was submitted and database search was conducted by an experienced librarian of all available studies in the English language from 1990 to June 8, 2022. Databases included Ovid MEDLINE(R) and Epub Ahead of Print, In‐Process & Other Non‐Indexed Citations and Daily, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, and Scopus.MethodologyInclusion criteria consisted of randomized controlled trials, prospective and retrospective longitudinal studies, and studies involving adults ≥18 years of age who underwent ulnar nerve decompression and/or transposition for UNE. Study quality and risk of bias were assessed using the National Heart, Lung, and Blood Institute (NHLBI) Study Quality of Assessment Tool. Certainty in evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. A meta‐analysis was not performed.SynthesisA total of 289 studies were screened, and 8 retrospective cohort studies met inclusion criteria comprising 762 patients. A decreased or absent preoperative sensory nerve action potential amplitude (SNAP) showed significance with worse postoperative outcomes. The presence of preoperative conduction block showed significance in higher quality studies. There was limited evidence for slow preoperative motor conduction velocities or preoperative electromyography (EMG) abnormalities and postoperative outcomes. Overall quality assessment demonstrated that two studies had “good,” four “fair,” and two “poor” quality of evidence. Certainty in evidence was “low” due to risk of bias.ConclusionsA decreased or absent preoperative ulnar SNAP may predict worse postoperative outcomes. Per higher quality studies, preoperative conduction block at the elbow may also predict worse postoperative outcomes. Careful interpretation is required with a full understanding of the limited evidence, risk of bias, and low certainty in evidence to support the use of preoperative EDX to predict postoperative outcomes in UNE.